• Advertising Industry's Largest Competition Recognizes Apyx Medical Device Campaign for Excellence in the Art of Advertising 

CLEARWATER, Fla., March 27, 2023 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX), the manufacturer of the proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion^®, today announced that it has won an award from the American Advertising Federation for the Best Integrated Advertising Campaign on its #ThisIsMe campaign. Developed in partnership with luxury branding agency Lombardo, the campaign represents the company's first ever direct-to-consumer brand campaign.

The national campaign is completely revolutionary for this industry, connecting with patients along their personal journey with approachable stories in their own words—empowering audiences to make the ultimate statement: #ThisIsMe.

"It is a pleasure to help make a positive impact for Renuvion and consumers with the #ThisIsMe campaign," says Rita Lombardo, Agency Partner and Director of Strategy. "To win an ADDY Award in addition just proves that the Renuvion vision and message deeply resonates with people and shifts the category forward."

"For too long the category has focused on what a person needed to fix, rather than letting people express themselves," says Jeff Hoffman, Vice President of Marketing. "By tying into the emotional benefit of Renuvion, #ThisIsMe speaks to a new generation of potential patients who are open about discussing cosmetic procedures."

The key personas targeted by the campaign represent strategic audiences, and the messaging shares how Renuvion allows individuals to define themselves, owning their look.

The visuals of the campaign are elevated to appeal to an audience that aligns more closely with beauty and fashion than with the type of imagery commonly associated with "medical advertising." In doing so, #ThisIsMe shifts the narrative around cosmetic procedures forward.

Renuvion reaches audiences throughout the U.S. with the #ThisIsMe campaign via TV spots accompanied by digital, social, and upcoming outdoor advertising as part of an aggressive omnichannel strategy to boost awareness and drive patients to physician providers. The brand and its devices are already a favorite among the top plastic surgeons and cosmetic physicians in the world.

About Apyx Medical Corporation

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people's lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion^® in the cosmetic surgery market and J-Plasma^® in the hospital surgical market. Renuvion^® and J-Plasma^® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

About Lombardo

Lombardo is a creative agency based on the Palm Beach waterfront, with offices in New York and Los Angeles. Since 2010, Lombardo gained a reputation for exceptional creative and bespoke service. Their work with both market leaders and challenger brands has changed the way industries operate and generated significant value for clients and communities alike. These attributes have seen them develop a client list that includes Fendi, Watches of Switzerland, and Anheuser-Busch.

Cautionary Statement on Forward-Looking Statements

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, any statements regarding the potential impact of the COVID-19 pandemic and the actions by governments, businesses and individuals in response to the situation; projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration, supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company's financial performance.

Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause the Company's actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company's ability to gain requisite approvals for its products from the U.S. Food and Drug Administration and other governmental and regulatory bodies, both domestically and internationally; the impact of the recent FDA Safety Communication on our business and operations; factors relating to the effects of the COVID-19 pandemic; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and the Company's other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Media Contact:

Jane Sparango
Coterie Media (for Renuvion)
This email address is being protected from spambots. You need JavaScript enabled to view it.
310-339-1214

Investor Relations Contact:

ICR Westwicke on behalf of Apyx Medical Corporation
Mike Piccinino, CFA
This email address is being protected from spambots. You need JavaScript enabled to view it.